Kim Hyung Seok, Choi Ji Yi, Baek Geum Ok, Yoon Moon Gyeong, Jang Se Ha, Han Ji Eun, Kim Soon Sun, Cheong Jae Youn, Jeong Jee-Yeong, Eun Jung Woo
Department of Biochemistry, Kosin University College of Medicine, 49267 Busan, Republic of Korea.
Department of Gastroenterology, Ajou University School of Medicine, 16499 Suwon, Republic of Korea.
Front Biosci (Landmark Ed). 2025 Jul 29;30(7):41684. doi: 10.31083/FBL41684.
Hepatocellular carcinoma (HCC) is the leading cause of cancer-related mortality worldwide. Despite advances in therapeutic approaches, the lack of effective biomarkers continues to limit early detection and prognostic evaluation. Pseudogenes, once considered nonfunctional, have emerged as regulators of biological processes in tumors and as potential biomarkers. This study aimed to identify and validate BMS1 Pseudogene 8 () as a liver-specific, clinically relevant diagnostic and prognostic biomarker in HCC.
A comprehensive survey of pseudogene expression across different stages of liver disease was performed and validated using clinical HCC samples. Correlation, enrichment, and competing endogenous RNA (ceRNA) analyses integrating matched microRNA (miRNA)-seq and mRNA-seq were used to explore the functional networks surrounding . Public RNA-seq datasets (GSE114564, The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA_LIHC)) were used to delineate differentially expressed pseudogenes, and 98 paired tumor and non-tumor tissues were assessed using quantitative reverse transcription polymerase chain reaction. Diagnostic and prognostic performances were evaluated using receiver operating characteristic curves and Kaplan-Meier statistics.
was markedly upregulated in HCC and was overexpressed in 25 other cancer types. Receiver operating characteristics analysis yielded an area under the curve of 0.81, underscoring the diagnostic utility. High expression and enrichment of cell cycle pathways were associated with poor survival. ceRNA screening revealed an inverse -miR-30c-2-3p correlation and concordant NME/NM23 nucleoside diphosphate kinase 6 () upregulation, with the /miR-30c-2-3p/ triad further stratifying patient outcomes.
Our findings highlight as a novel liver-specific biomarker with substantial diagnostic and prognostic value in HCC. Its diagnostic utility suggests its potential application in early detection and personalized treatment strategies, contributing to improved patient outcomes.
肝细胞癌(HCC)是全球癌症相关死亡的主要原因。尽管治疗方法取得了进展,但缺乏有效的生物标志物仍然限制了早期检测和预后评估。假基因曾被认为是无功能的,现已成为肿瘤生物学过程的调节因子和潜在的生物标志物。本研究旨在鉴定和验证BMS1假基因8()作为HCC中肝脏特异性、临床相关的诊断和预后生物标志物。
使用临床HCC样本对不同肝病阶段的假基因表达进行全面调查并验证。整合匹配的微小RNA(miRNA)测序和信使核糖核酸(mRNA)测序的相关性、富集和竞争性内源性RNA(ceRNA)分析用于探索围绕的功能网络。公共RNA测序数据集(GSE114564,癌症基因组图谱-肝细胞癌(TCGA_LIHC))用于描绘差异表达的假基因,并使用定量逆转录聚合酶链反应评估98对肿瘤和非肿瘤组织。使用受试者工作特征曲线和Kaplan-Meier统计评估诊断和预后性能。
在HCC中显著上调,并在其他25种癌症类型中过表达。受试者工作特征分析得出曲线下面积为0.81,突出了其诊断效用。高表达和细胞周期途径的富集与较差的生存率相关。ceRNA筛选揭示了与-miR-30c-2-3p的反向相关性以及核苷二磷酸激酶6()的一致上调,/miR-30c-2-3p/三联体进一步对患者预后进行分层。
我们的研究结果突出了作为一种新型肝脏特异性生物标志物在HCC中具有重要的诊断和预后价值。其诊断效用表明其在早期检测和个性化治疗策略中的潜在应用,有助于改善患者预后。